COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study

Autores
Huespe, Ivan; Ferraris, Augusto; Lalueza, Antonio; Valdez, Pascual; Peroni, María Leticia; Cayetti, Luis A.; Mirofsky, Matias A.; Boietti, Bruno Rafael; Gómez Huelgas, Ricardo; Casas Rojo, José M.; Antón Santos, Juan M.; Núñez Cortés, Jesús M.; Lumbreras, Carlos; Ramos Rincón, Jose Manuel; Barrio, Noelia G.; Pedrera Jiménez, Miguel; Martin Escalante, María D.; Ruiz, Francisco R.; Onieva García, María Á.; Toso, Carlos R.; Risk, Marcelo; Klén, Riku; Pollán, Javier A.; Gómez Varela, David
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The aim of this study was to analyze whether the coronavirus disease 2019 (COVID-19) vaccine reduces mortality in patients with moderate or severe COVID-19 disease requiring oxygen therapy. A retrospective cohort study, with data from 148 hospitals in both Spain (111 hospitals) and Argentina (37 hospitals), was conducted. We evaluated hospitalized patients for COVID-19 older than 18 years with oxygen requirements. Vaccine protection against death was assessed through a multivariable logistic regression and propensity score matching. We also performed a subgroup analysis according to vaccine type. The adjusted model was used to determine the population attributable risk. Between January 2020 and May 2022, we evaluated 21,479 COVID-19 hospitalized patients with oxygen requirements. Of these, 338 (1.5%) patients received a single dose of the COVID-19 vaccine and 379 (1.8%) were fully vaccinated. In vaccinated patients, mortality was 20.9% (95% confidence interval [CI]: 17.9–24), compared to 19.5% (95% CI: 19–20) in unvaccinated patients, resulting in a crude odds ratio (OR) of 1.07 (95% CI: 0.89–1.29; p = 0.41). However, after considering the multiple comorbidities in the vaccinated group, the adjusted OR was 0.73 (95% CI: 0.56–0.95; p = 0.02) with a population attributable risk reduction of 4.3% (95% CI: 1–5). The higher risk reduction for mortality was with messenger RNA (mRNA) BNT162b2 (Pfizer) (OR 0.37; 95% CI: 0.23–0.59; p < 0.01), ChAdOx1 nCoV-19 (AstraZeneca) (OR 0.42; 95% CI: 0.20–0.86; p = 0.02), and mRNA-1273 (Moderna) (OR 0.68; 95% CI: 0.41–1.12; p = 0.13), and lower with Gam-COVID-Vac (Sputnik) (OR 0.93; 95% CI: 0.6–1.45; p = 0.76). COVID-19 vaccines significantly reduce the probability of death in patients suffering from a moderate or severe disease (oxygen therapy).
Fil: Huespe, Ivan. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Ferraris, Augusto. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Lalueza, Antonio. 12 de Octubre University Hospital; España
Fil: Valdez, Pascual. Hospital General de Agudos Dalmacio Velez Sarsfield ; Gobierno de la Ciudad Autonoma de Buenos Aires;
Fil: Peroni, María Leticia. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Cayetti, Luis A.. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Mirofsky, Matias A.. Hospital Municipal Doctor Leónidas Lucero; Argentina
Fil: Boietti, Bruno Rafael. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Gómez Huelgas, Ricardo. Universidad de Málaga; España
Fil: Casas Rojo, José M.. Infanta Cristina University Hospital; España
Fil: Antón Santos, Juan M.. Infanta Cristina University Hospital; España
Fil: Núñez Cortés, Jesús M.. Hospital General Universitario Gregorio Marañón (hosp Gral Univ G. Marañón); España
Fil: Lumbreras, Carlos. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; España
Fil: Ramos Rincón, Jose Manuel. Universidad de Miguel Hernández; España
Fil: Barrio, Noelia G.. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; España
Fil: Pedrera Jiménez, Miguel. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; España
Fil: Martin Escalante, María D.. Costa del Sol Hospital; España
Fil: Ruiz, Francisco R.. Costa del Sol Hospital; España
Fil: Onieva García, María Á.. Costa del Sol Hospital; España
Fil: Toso, Carlos R.. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Risk, Marcelo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina
Fil: Klén, Riku. University of Turku; Finlandia
Fil: Pollán, Javier A.. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Gómez Varela, David. Universidad de Viena; Austria
Materia
COVID-19
COVID-19 VACCINES
HOSPITALIZATION
OXYGEN THERAPY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/227961
Acceder
id CONICETDig_91ab43a4764fe50b6af829c585e3fd78
oai_identifier_str oai:ri.conicet.gov.ar:11336/227961
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort studyHuespe, IvanFerraris, AugustoLalueza, AntonioValdez, PascualPeroni, María LeticiaCayetti, Luis A.Mirofsky, Matias A.Boietti, Bruno RafaelGómez Huelgas, RicardoCasas Rojo, José M.Antón Santos, Juan M.Núñez Cortés, Jesús M.Lumbreras, CarlosRamos Rincón, Jose ManuelBarrio, Noelia G.Pedrera Jiménez, MiguelMartin Escalante, María D.Ruiz, Francisco R.Onieva García, María Á.Toso, Carlos R.Risk, MarceloKlén, RikuPollán, Javier A.Gómez Varela, DavidCOVID-19COVID-19 VACCINESHOSPITALIZATIONOXYGEN THERAPYhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3The aim of this study was to analyze whether the coronavirus disease 2019 (COVID-19) vaccine reduces mortality in patients with moderate or severe COVID-19 disease requiring oxygen therapy. A retrospective cohort study, with data from 148 hospitals in both Spain (111 hospitals) and Argentina (37 hospitals), was conducted. We evaluated hospitalized patients for COVID-19 older than 18 years with oxygen requirements. Vaccine protection against death was assessed through a multivariable logistic regression and propensity score matching. We also performed a subgroup analysis according to vaccine type. The adjusted model was used to determine the population attributable risk. Between January 2020 and May 2022, we evaluated 21,479 COVID-19 hospitalized patients with oxygen requirements. Of these, 338 (1.5%) patients received a single dose of the COVID-19 vaccine and 379 (1.8%) were fully vaccinated. In vaccinated patients, mortality was 20.9% (95% confidence interval [CI]: 17.9–24), compared to 19.5% (95% CI: 19–20) in unvaccinated patients, resulting in a crude odds ratio (OR) of 1.07 (95% CI: 0.89–1.29; p = 0.41). However, after considering the multiple comorbidities in the vaccinated group, the adjusted OR was 0.73 (95% CI: 0.56–0.95; p = 0.02) with a population attributable risk reduction of 4.3% (95% CI: 1–5). The higher risk reduction for mortality was with messenger RNA (mRNA) BNT162b2 (Pfizer) (OR 0.37; 95% CI: 0.23–0.59; p < 0.01), ChAdOx1 nCoV-19 (AstraZeneca) (OR 0.42; 95% CI: 0.20–0.86; p = 0.02), and mRNA-1273 (Moderna) (OR 0.68; 95% CI: 0.41–1.12; p = 0.13), and lower with Gam-COVID-Vac (Sputnik) (OR 0.93; 95% CI: 0.6–1.45; p = 0.76). COVID-19 vaccines significantly reduce the probability of death in patients suffering from a moderate or severe disease (oxygen therapy).Fil: Huespe, Ivan. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina. Universidad de Buenos Aires. Facultad de Medicina; ArgentinaFil: Ferraris, Augusto. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaFil: Lalueza, Antonio. 12 de Octubre University Hospital; EspañaFil: Valdez, Pascual. Hospital General de Agudos Dalmacio Velez Sarsfield ; Gobierno de la Ciudad Autonoma de Buenos Aires;Fil: Peroni, María Leticia. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaFil: Cayetti, Luis A.. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaFil: Mirofsky, Matias A.. Hospital Municipal Doctor Leónidas Lucero; ArgentinaFil: Boietti, Bruno Rafael. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaFil: Gómez Huelgas, Ricardo. Universidad de Málaga; EspañaFil: Casas Rojo, José M.. Infanta Cristina University Hospital; EspañaFil: Antón Santos, Juan M.. Infanta Cristina University Hospital; EspañaFil: Núñez Cortés, Jesús M.. Hospital General Universitario Gregorio Marañón (hosp Gral Univ G. Marañón); EspañaFil: Lumbreras, Carlos. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; EspañaFil: Ramos Rincón, Jose Manuel. Universidad de Miguel Hernández; EspañaFil: Barrio, Noelia G.. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; EspañaFil: Pedrera Jiménez, Miguel. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; EspañaFil: Martin Escalante, María D.. Costa del Sol Hospital; EspañaFil: Ruiz, Francisco R.. Costa del Sol Hospital; EspañaFil: Onieva García, María Á.. Costa del Sol Hospital; EspañaFil: Toso, Carlos R.. Universidad de Buenos Aires. Facultad de Medicina; ArgentinaFil: Risk, Marcelo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; ArgentinaFil: Klén, Riku. University of Turku; FinlandiaFil: Pollán, Javier A.. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaFil: Gómez Varela, David. Universidad de Viena; AustriaWiley-liss, div John Wiley & Sons Inc.2023-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/227961Huespe, Ivan; Ferraris, Augusto; Lalueza, Antonio; Valdez, Pascual; Peroni, María Leticia; et al.; COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study; Wiley-liss, div John Wiley & Sons Inc.; Journal of Medical Virology; 95; 5; 5-2023; 1-100146-6615CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1002/jmv.28786info:eu-repo/semantics/altIdentifier/doi/10.1002/jmv.28786info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:11:20Zoai:ri.conicet.gov.ar:11336/227961instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:11:20.892CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study
title COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study
spellingShingle COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study
Huespe, Ivan
COVID-19
COVID-19 VACCINES
HOSPITALIZATION
OXYGEN THERAPY
title_short COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study
title_full COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study
title_fullStr COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study
title_full_unstemmed COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study
title_sort COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study
dc.creator.none.fl_str_mv Huespe, Ivan
Ferraris, Augusto
Lalueza, Antonio
Valdez, Pascual
Peroni, María Leticia
Cayetti, Luis A.
Mirofsky, Matias A.
Boietti, Bruno Rafael
Gómez Huelgas, Ricardo
Casas Rojo, José M.
Antón Santos, Juan M.
Núñez Cortés, Jesús M.
Lumbreras, Carlos
Ramos Rincón, Jose Manuel
Barrio, Noelia G.
Pedrera Jiménez, Miguel
Martin Escalante, María D.
Ruiz, Francisco R.
Onieva García, María Á.
Toso, Carlos R.
Risk, Marcelo
Klén, Riku
Pollán, Javier A.
Gómez Varela, David
author Huespe, Ivan
author_facet Huespe, Ivan
Ferraris, Augusto
Lalueza, Antonio
Valdez, Pascual
Peroni, María Leticia
Cayetti, Luis A.
Mirofsky, Matias A.
Boietti, Bruno Rafael
Gómez Huelgas, Ricardo
Casas Rojo, José M.
Antón Santos, Juan M.
Núñez Cortés, Jesús M.
Lumbreras, Carlos
Ramos Rincón, Jose Manuel
Barrio, Noelia G.
Pedrera Jiménez, Miguel
Martin Escalante, María D.
Ruiz, Francisco R.
Onieva García, María Á.
Toso, Carlos R.
Risk, Marcelo
Klén, Riku
Pollán, Javier A.
Gómez Varela, David
author_role author
author2 Ferraris, Augusto
Lalueza, Antonio
Valdez, Pascual
Peroni, María Leticia
Cayetti, Luis A.
Mirofsky, Matias A.
Boietti, Bruno Rafael
Gómez Huelgas, Ricardo
Casas Rojo, José M.
Antón Santos, Juan M.
Núñez Cortés, Jesús M.
Lumbreras, Carlos
Ramos Rincón, Jose Manuel
Barrio, Noelia G.
Pedrera Jiménez, Miguel
Martin Escalante, María D.
Ruiz, Francisco R.
Onieva García, María Á.
Toso, Carlos R.
Risk, Marcelo
Klén, Riku
Pollán, Javier A.
Gómez Varela, David
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19
COVID-19 VACCINES
HOSPITALIZATION
OXYGEN THERAPY
topic COVID-19
COVID-19 VACCINES
HOSPITALIZATION
OXYGEN THERAPY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The aim of this study was to analyze whether the coronavirus disease 2019 (COVID-19) vaccine reduces mortality in patients with moderate or severe COVID-19 disease requiring oxygen therapy. A retrospective cohort study, with data from 148 hospitals in both Spain (111 hospitals) and Argentina (37 hospitals), was conducted. We evaluated hospitalized patients for COVID-19 older than 18 years with oxygen requirements. Vaccine protection against death was assessed through a multivariable logistic regression and propensity score matching. We also performed a subgroup analysis according to vaccine type. The adjusted model was used to determine the population attributable risk. Between January 2020 and May 2022, we evaluated 21,479 COVID-19 hospitalized patients with oxygen requirements. Of these, 338 (1.5%) patients received a single dose of the COVID-19 vaccine and 379 (1.8%) were fully vaccinated. In vaccinated patients, mortality was 20.9% (95% confidence interval [CI]: 17.9–24), compared to 19.5% (95% CI: 19–20) in unvaccinated patients, resulting in a crude odds ratio (OR) of 1.07 (95% CI: 0.89–1.29; p = 0.41). However, after considering the multiple comorbidities in the vaccinated group, the adjusted OR was 0.73 (95% CI: 0.56–0.95; p = 0.02) with a population attributable risk reduction of 4.3% (95% CI: 1–5). The higher risk reduction for mortality was with messenger RNA (mRNA) BNT162b2 (Pfizer) (OR 0.37; 95% CI: 0.23–0.59; p < 0.01), ChAdOx1 nCoV-19 (AstraZeneca) (OR 0.42; 95% CI: 0.20–0.86; p = 0.02), and mRNA-1273 (Moderna) (OR 0.68; 95% CI: 0.41–1.12; p = 0.13), and lower with Gam-COVID-Vac (Sputnik) (OR 0.93; 95% CI: 0.6–1.45; p = 0.76). COVID-19 vaccines significantly reduce the probability of death in patients suffering from a moderate or severe disease (oxygen therapy).
Fil: Huespe, Ivan. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Ferraris, Augusto. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Lalueza, Antonio. 12 de Octubre University Hospital; España
Fil: Valdez, Pascual. Hospital General de Agudos Dalmacio Velez Sarsfield ; Gobierno de la Ciudad Autonoma de Buenos Aires;
Fil: Peroni, María Leticia. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Cayetti, Luis A.. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Mirofsky, Matias A.. Hospital Municipal Doctor Leónidas Lucero; Argentina
Fil: Boietti, Bruno Rafael. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Gómez Huelgas, Ricardo. Universidad de Málaga; España
Fil: Casas Rojo, José M.. Infanta Cristina University Hospital; España
Fil: Antón Santos, Juan M.. Infanta Cristina University Hospital; España
Fil: Núñez Cortés, Jesús M.. Hospital General Universitario Gregorio Marañón (hosp Gral Univ G. Marañón); España
Fil: Lumbreras, Carlos. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; España
Fil: Ramos Rincón, Jose Manuel. Universidad de Miguel Hernández; España
Fil: Barrio, Noelia G.. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; España
Fil: Pedrera Jiménez, Miguel. 12 de Octubre University Hospital; España. Universidad Complutense de Madrid; España
Fil: Martin Escalante, María D.. Costa del Sol Hospital; España
Fil: Ruiz, Francisco R.. Costa del Sol Hospital; España
Fil: Onieva García, María Á.. Costa del Sol Hospital; España
Fil: Toso, Carlos R.. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Risk, Marcelo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina
Fil: Klén, Riku. University of Turku; Finlandia
Fil: Pollán, Javier A.. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Gómez Varela, David. Universidad de Viena; Austria
description The aim of this study was to analyze whether the coronavirus disease 2019 (COVID-19) vaccine reduces mortality in patients with moderate or severe COVID-19 disease requiring oxygen therapy. A retrospective cohort study, with data from 148 hospitals in both Spain (111 hospitals) and Argentina (37 hospitals), was conducted. We evaluated hospitalized patients for COVID-19 older than 18 years with oxygen requirements. Vaccine protection against death was assessed through a multivariable logistic regression and propensity score matching. We also performed a subgroup analysis according to vaccine type. The adjusted model was used to determine the population attributable risk. Between January 2020 and May 2022, we evaluated 21,479 COVID-19 hospitalized patients with oxygen requirements. Of these, 338 (1.5%) patients received a single dose of the COVID-19 vaccine and 379 (1.8%) were fully vaccinated. In vaccinated patients, mortality was 20.9% (95% confidence interval [CI]: 17.9–24), compared to 19.5% (95% CI: 19–20) in unvaccinated patients, resulting in a crude odds ratio (OR) of 1.07 (95% CI: 0.89–1.29; p = 0.41). However, after considering the multiple comorbidities in the vaccinated group, the adjusted OR was 0.73 (95% CI: 0.56–0.95; p = 0.02) with a population attributable risk reduction of 4.3% (95% CI: 1–5). The higher risk reduction for mortality was with messenger RNA (mRNA) BNT162b2 (Pfizer) (OR 0.37; 95% CI: 0.23–0.59; p < 0.01), ChAdOx1 nCoV-19 (AstraZeneca) (OR 0.42; 95% CI: 0.20–0.86; p = 0.02), and mRNA-1273 (Moderna) (OR 0.68; 95% CI: 0.41–1.12; p = 0.13), and lower with Gam-COVID-Vac (Sputnik) (OR 0.93; 95% CI: 0.6–1.45; p = 0.76). COVID-19 vaccines significantly reduce the probability of death in patients suffering from a moderate or severe disease (oxygen therapy).
publishDate 2023
dc.date.none.fl_str_mv 2023-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/227961
Huespe, Ivan; Ferraris, Augusto; Lalueza, Antonio; Valdez, Pascual; Peroni, María Leticia; et al.; COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study; Wiley-liss, div John Wiley & Sons Inc.; Journal of Medical Virology; 95; 5; 5-2023; 1-10
0146-6615
CONICET Digital
CONICET
url http://hdl.handle.net/11336/227961
identifier_str_mv Huespe, Ivan; Ferraris, Augusto; Lalueza, Antonio; Valdez, Pascual; Peroni, María Leticia; et al.; COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes: A multicontinental cohort study; Wiley-liss, div John Wiley & Sons Inc.; Journal of Medical Virology; 95; 5; 5-2023; 1-10
0146-6615
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1002/jmv.28786
info:eu-repo/semantics/altIdentifier/doi/10.1002/jmv.28786
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley-liss, div John Wiley & Sons Inc.
publisher.none.fl_str_mv Wiley-liss, div John Wiley & Sons Inc.
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083261566025728
score 13.22299

Publicaciones similares